scholarly journals Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell–Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303

2011 ◽  
Vol 17 (9) ◽  
pp. 1343-1351 ◽  
Author(s):  
Steven M. Devine ◽  
Shelly Carter ◽  
Robert J. Soiffer ◽  
Marcelo C. Pasquini ◽  
Parameswaran N. Hari ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Stem Cell ◽  
Peripheral Blood Stem Cell ◽  
Marrow Transplant ◽  
Myelogenous Leukemia ◽  
Graft Versus Host ◽  
Blood And Marrow Transplant ◽  
Acute Myelogenous ◽  
First Remission ◽  
Blood Stem Cell Transplantation

scholarly journals ID3012 Evaluation of HLA-identical sibling allogenic peripheral blood stem cell transplantation for acute myelogenous leukemia at BTH, Vietnam

2017 ◽  
Vol 4 (S) ◽  
pp. 24
Author(s):  
Man Van Huynh
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
Myelogenous Leukemia ◽  
Graft Versus Host ◽  
Acute Myelogenous ◽  
Blood Stem Cell Transplantation

Background: the purposes of this study were to assess the efficacy of HLA-identical sibling allogenic peripheral blood stem cell transplantation in the treatment for acute myelogenous leukemia (AML) at Blood transfusion and hematology hospital at Ho Chi Minh city.   Methods: retrospective study, case series.   Results: from June 2005 to September 2016, there were 47 AML patients included 24 males and 23 females, with median age was 36 years old. Engraftment was achieved in 47 patients (100%). The median number of transfused CD34+ cells was 7.5 x 106/kg. The median time for neutrophil engraftment and platelet engraftment were 11 ± 2.8 days and 12.5 ± 10.1 days respectively. Oral mucositis occurred in 38 patients (80.9%), febrile neutropenia in 42 patients (89.4%), acute graft-versus-host disease (aGvHD) in 14 patients (29.8%), chronic graft-versus-host disease (cGvHD) in 10 patients (21.3%), and VOD in 6 patients (12.8%). Transplant-related mortality (TRM) was 4 patients (8.5%). Median follow-up time was 52.26 months. Patients remained alive were 27 (57.4%). The 5-year overall survival (OS) and disease-free survival (DFS) were 55% and 54% respectively.   Conclusion: HLA-identical sibling allogeneic blood stem cell transplantation can reconstruct hematopoiesis quickly and is a favorable therapeutic method for AML patients. Further development and improvement of hematopoietic stem cell transplantation techniques along with graduated and individualized therapy are expected to provide better outcomes and improved quality of life for AML patients.

Sign in / Sign up

Export Citation Format

Share Document